CSF2 and cancer: In a phase I clinical trial, Jaffee et al. [80] used allogeneic GM-CSF-secreting whole-cell tumor vaccine for pancreatic cancer, based on the concept that the GM-CSF localization in the implanted tumor environment together with the shared tumor antigen expressed by the primary cancer would effectively induce an antitumor immune response.